Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600507 | 0.95 | BCHE (0.44) | BCHEACHEHRH3PARP1DRD3 | |
| SCHEMBL31721289 | 0.91 | BCHE (0.53) | BCHEACHEHRH3PARP1CHKA | |
| SCHEMBL3320134 | 0.91 | BCHE (0.53) | BCHEACHEHRH3PARP1CHKA | |
| SCHEMBL29556580 | 0.87 | SIGMAR1 (0.41) | HRH3ADORA2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL17797162 | 0.87 | SIGMAR1 (0.41) | HRH3ADORA2AHSD17B10KDM4EALDH1A1 | |
| SCHEMBL17805292 | 0.82 | DRD2 (0.53) | BCHEACHEHSD17B10KDM4E | |
| SCHEMBL16728791 | 0.81 | BCHE (0.44) | BCHEACHEPARP1CHKAKDM4E | |
| SCHEMBL465875 | 0.81 | BCHE (0.53) | BCHEACHEPARP1L3MBTL1HSD17B10 | |
| SCHEMBL31186159 | 0.81 | BCHE (0.53) | BCHEACHEPARP1CHKAL3MBTL1 | |
| SCHEMBL19600508 | 0.80 | ALDH1A1 (0.37) | HRH3DRD3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3909948-B1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2024-02-28 | — | — | EP | disclosed |
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-05-12 | — | — | US | disclosed |
| US-11266754-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-03-08 | — | — | US | disclosed |
| EP-3909948-A1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3227272-B1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2021-07-07 | — | — | EP | disclosed |
| US-20200038527-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2020-02-06 | — | — | US | disclosed |
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-11-16 | — | — | US | disclosed |
| WO-2016087667-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
| EP-3029032-A1 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | Centre National de la Recherche Scientifique (CNRS) (FR) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038527-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | BCHE 2993/4885ACHE 2440/4885HRH3 1008/4885 |
| US-20220143230-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | BCHE 2993/4885ACHE 2440/4885HRH3 1008/4885 |
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | BCHE 2993/4885ACHE 2440/4885HRH3 1008/4885 |
| US-11266754-B2 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | AP2A2, ATP2A2, SLC20A2 | BCHE 2993/4885ACHE 2440/4885HRH3 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.